Last reviewed · How we verify
fecal calprotectin concentration
At a glance
| Generic name | fecal calprotectin concentration |
|---|---|
| Sponsor | CHU de Reims |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Improving Patient Outcomes Through the Implementation of an IBD Biologic Care Pathway (NA)
- Precise Infliximab Exposure and Pharmacodynamic Control (PHASE2, PHASE3)
- Quantification of Fecal Calprotectin Concentration Difference Between Infants Aged Under 4 Months Old Suffering From Functional Gastrointestinal Disorders (FGID) and Infants Aged Under 4 Months Old Free From Disorders : a Transversal Case-control Monocentric Study (NA)
- Efficacy of Calprotectin as A Marker For the Pathogenicity of Blastocystis Infection
- Monitor Faecal Calprotectin Concentration in Infants With Heart Defects
- Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease
- Impedance Spectroscopy for Obstetric Anal Sphincter Injuries Detection (NA)
- Impedance Spectroscopy in Detection of Obstetric Anal Sphincter Injuries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |